Age Related Macular Degeneration Clinical Trial
Official title:
Pilot Study of WA-NG Telescope Prosthesis in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration
Verified date | April 2014 |
Source | VisionCare Ophthalmic Technologies, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | Israel: Ministry of Health |
Study type | Interventional |
This is a pilot study to evaluate the safety of the Model WA-NG telescope prosthesis in patients with bilateral moderate to profound central vision impairment due to end-stage age-related macular degeneration.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: Bi-lateral, stable, moderate to profound (20/80 to 20/800) central vision impairment due to bilateral scotoma associated with end-stage macular degeneration, defined as retinal finds of bilateral, geographic atrophy or disciform scar with foveal involvment. Phakic in the operative eye. Must achieve a 5 letter improved with external telescope simulator. Exclusion Criteria: Evidence of active CNV or any ophthalmic pathology that compromises peripheral vision of fellow eye or predisposes eye rubbing. Previous intraocular of corneal surgery of any kind in operative eye. Retinal disease, optic nerve disease, diabetic retinopathy, retinal tears, or any introcular tumor or medical or ophthalmic condition that in the opinion of the investigator renders the subject unsuitable for participation. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Israel | Assaf Harofeh Medical Center | Zerifin |
Lead Sponsor | Collaborator |
---|---|
VisionCare Ophthalmic Technologies, Inc. |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety | Positional stability assessed by slit lamp examination and anterior segment OCT | 12 months | Yes |
Secondary | Safety | adverse events | 12 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Recruiting |
NCT04929756 -
Eye Movement Rehabilitation in Low Vision Patients
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 |